Alnylam: T. Rowe Price reports 7.5% passive stake
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Alnylam Pharmaceuticals, Inc. (ALNY) was the subject of a Schedule 13G in which reporting person T. Rowe Price Investment Management, Inc. reported 10,017,904 shares, or 7.5% of the class, as beneficially owned as of September 30, 2026. It reported sole voting power over 9,530,952 shares and sole dispositive power over 10,017,904 shares, with no shared voting or dispositive power. Ellen York, Vice President, signed the statement.
Key Figures
Key Terms
Beneficial ownership regulatory
Sole Voting Power regulatory
Sole Dispositive Power regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.